Table 2.
List of clinical research series of product candidates that included phases I–III
| Product | Country | Phase I start | Phase I complete | Phase II start | Phase II complete | Phase III start | Phase III complete | Approval | Phase I start–phase III complete (months) |
|---|---|---|---|---|---|---|---|---|---|
| TissueGene-C (Invossa™) | Korea | Feb 2007 | Sep 2008 | Aug 2009 | Jun 2014 | Nov 2013 | Aug 2015 | Jul 2017 | 103 |
| NCT02341391 |
NCT02341378 NCT01671072 NCT01825811 |
NCT02072070 | |||||||
| TissueGene-C | US | Jan 2007 | May 2010 | May 2011 | Oct 2014 | Apr 2018 | (Jun 2021) | – | (176) |
| NCT00599248 | NCT01221441 |
NCT03203330 NCT03291470 |
|||||||
| rexlemestrocel-L (NeoFuse™) | US/Australia | Oct 2007 | – | Jun 2010 | Jul 2015 | Mar 2015 | (Feb 2020) | – | (150) |
| NCT00549913 |
NCT01097486 NCT01106417 NCT01290367 |
NCT02412735 | |||||||